Andere Sprachen NATCO Pharma Limited

Aktien

A2ABRD

INE987B01026

NATCOPHARM

Markt geschlossen - NSE India S.E. Andere Börsenplätze 13:43:49 03.05.2024			% 5 Tage	% 1. Jan.
1 034 ^INR	+2,27 %		+0,60 %	+27,45 %

09.04.	Natco Pharma erhält nach Inspektion von Kothur, Indien, einen Warnbrief der US FDA	MT
27.03.	NATCO Pharma Limited gibt die Ernennung von Verwaltungsratsmitgliedern bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Natco Pharma Gets US FDA Warning Letter after Inspection of Kothur, India Unit	09.04.
NATCO Pharma Limited Announces Board Appointments	27.03.
INDIA STOCKS-Indian shares erase early gains, weighed down by IT stocks	19.02.
NATCO Pharma Limited Revises Earnings Guidance for the Fiscal Year 2024	15.02.
Corporate Action-Board Approves Third Interim Dividend for the Financial Year 2023-24, Payable on 4 March 2024	14.02.
NATCO Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14.02.
Cellogen Therapeutics announced that it has received $2 million in funding from NATCO Pharma Limited	17.01.
Floods Disrupt Operations of Natco Pharma's Plant in Tamil Nadu, India	07.12.
Natco Pharma's Consolidated Profit Soars in Fiscal Q2, Declares Second Interim Dividend	14.11.
NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2023-24, Payable on 1 December, 2023	14.11.
NATCO Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	14.11.
US FDA Clears Natco Pharma's Pharmacovigilance Department in Hyderabad, India	02.11.
Redcliffe Hygiene Private Limited announced that it has received INR 248 million in funding from Rainmatter, Alkemi Growth Capital LLP, NATCO Pharma Limited	12.09.23
Indian Equities End Higher for Sixth Straight Day, Buoyed by Banking, Public Sector Enterprises	08.09.23
Natco Pharma, Three Others Face Antitrust Violation Raps in US; Natco Pharma Shares Drop 3%	08.09.23
Bristol Myers accused of illegal tactics to keep Pomalyst monopoly in lawsuit	06.09.23
Indian shares set to open flat on caution ahead of GDP data	31.08.23
Natco Pharma to Form UK Arm	09.08.23
NATCO Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	09.08.23
NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2023-24	09.08.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen NATCO Pharma Limited

Aktien

A2ABRD

INE987B01026

NATCOPHARM

Andere Sprachen

Filter